Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
The Critical Interplay: CKD, HF, and HyperkaleAmia
James Burton, DM, FRCP
Javed Butler, MD
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Javed Butler, MD, MPH, MBA
Future Directions in Managing Hyperkalemia in CKD and HF
Difelikefalin: Managing CKD-aP for Improved Quality of Life
Jörg Latus, MD
IgA Nephropathy Updates: Evolving Guidelines and Practical Strategies
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Loreto Gesualdo, MD, FERA
Can We Do Better in IgAN?
Jonathan Barratt, MD, PhD
Annette Bruchfeld, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Separating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.